# Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

> **NCT02834780** · PHASE1 · COMPLETED · sponsor: **H3 Biomedicine Inc.** · enrollment: 128 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Hepatocellular Carcinoma
- Liver Cancer
- Liver Neoplasms
- Hepatic Cancer
- Hepatic Carcinoma

## Interventions

- **DRUG:** H3B-6527

## Key facts

- **NCT ID:** NCT02834780
- **Lead sponsor:** H3 Biomedicine Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-28
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-02-23
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2023-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02834780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02834780, "Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02834780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*